Stratos Wealth Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Stratos Wealth Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,005	Closed	-$413K	–	664
2025 Q4	$413K	Hold	4,005	–	–	0.02%	475
2025 Q3	$362K	Sell	4,005 -61	-2%	-$5.34K	0.02%	512
2025 Q2	$358K	Sell	4,066 -31	-0.8%	-$2.69K	0.02%	507
2025 Q1	$373K	Sell	4,097 -10,095	-71%	-$909K	0.02%	502
2024 Q4	$1.22M	Buy	14,192 +1,133	+9%	+$102K	0.06%	300
2024 Q3	$1.24M	Buy	13,059 +3,778	+41%	+$359K	0.06%	317
2024 Q2	$849K	Buy	+9,281	New	+$829K	0.04%	361

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

Stratos Wealth Advisors's PPH Position: Q1 2026 in Review

Stratos Wealth Advisors sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2026, closing a stake of 4,005 shares — an estimated $413K sold.

Stratos Wealth Advisors first reported a position in PPH in Q2 2024 and held it in 7 quarters. The position peaked at $1.24M in Q3 2024. 147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

Stratos Wealth Advisors reported no remaining VanEck Pharmaceutical ETF position as of Q1 2026 after selling out during the quarter.
Stratos Wealth Advisors sold 4,005 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $413K.
Stratos Wealth Advisors first reported a position in VanEck Pharmaceutical ETF in Q2 2024 and held it in 7 quarters.
Stratos Wealth Advisors's VanEck Pharmaceutical ETF position peaked at $1.24M in Q3 2024.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on Stratos Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.